Premium
Hepatic veno‐occlusive disease after tranexamic acid administration in patients undergoing allogeneic hematopoietic stem cell transplantation
Author(s) -
Mori Takehiko,
Aisa Yoshinobu,
Shimizu Takayuki,
Yamazaki Rie,
Mihara Ai,
Yajima Tomoharu,
Hibi Toshifumi,
Ikeda Yasuo,
Okamoto Shinichiro
Publication year - 2007
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.20958
Subject(s) - tranexamic acid , medicine , discontinuation , antifibrinolytic , hematopoietic stem cell transplantation , transplantation , adverse effect , plasminogen activator , surgery , blood loss
Tranexamic acid is one of the widely used antifibrinolytic agents. In spite of its effective inhibitory activity against plasminogen, thromboembolic adverse events caused by tranexamic acid are rare. We encountered three recipients of allogeneic hematopoietic stem cell transplantation (HSCT) who developed hepatic veno‐occlusive disease (VOD) shortly after the administration of tranexamic acid. Hepatic VOD was resolved completely in all patients with the discontinuation of the drug, and with supportive measures with or without intravenous tissue plasminogen activator administration. These findings suggest that administration of tranexamic acid could be one of the possible risk factors for developing hepatic VOD in HSCT recipients. Am. J. Hematol., 2007. © 2007 Wiley‐Liss, Inc.